News
-
-
-
-
-
-
-
PRESS RELEASE
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Quantum BioPharma reports financial results for Q4 & FY 2024, highlights completion of unbuzzd clinical trial and Phase 1 of Lucid-21-302 multiple sclerosis drug, advancing pipeline of products -
-
-
PRESS RELEASE
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology